Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York Wells Fargo Healthcare Conference on September 5 in Boston Baird 2024 Global Healthcare Conference on September...
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.3 | -1.3999569244 | 92.86 | 96.4714 | 89.24 | 475972 | 92.86930456 | CS |
4 | 3.21 | 3.63327674024 | 88.35 | 97 | 87.57 | 456109 | 92.53411745 | CS |
12 | 10.37 | 12.7725089297 | 81.19 | 97 | 72.21 | 506994 | 86.95860591 | CS |
26 | 7.96 | 9.52153110048 | 83.6 | 97 | 64.11 | 592664 | 79.28378416 | CS |
52 | 18.91 | 26.0289057123 | 72.65 | 98.4 | 55.02 | 652057 | 76.87696935 | CS |
156 | 59.01 | 181.290322581 | 32.55 | 98.4 | 20.63 | 929612 | 58.71488773 | CS |
260 | 64.75 | 241.514360313 | 26.81 | 125.25 | 13.64 | 850451 | 58.59491241 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.